Search Results
CAPTIVATE and beyond: combination therapies for CLL
CAPTIVATE: 1-year DFS results from the MRD cohort in CLL
Updates from CAPTIVATE: ibrutinib and venetoclax for CLL
William Wierda | Ibrutinib and venetoclax combination for first-line CLL: CAPTIVATE phase II trial
Updates in CLL - 2023 Best of Hematology Conference
Combination of Novel Agents in CLL: Is this the Final Answer?
Key highlights in CLL: clinical trial updates & the role of combination therapies and novel BTKis
Rewriting the Script in CLL With Modern Targeted and Next-Gen Options
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study
Pushing Boundaries in CLL: Targeted Therapy, Novel Combinations, and Precision Medicine
Beyond ibrutinib and venetoclax, what are other novel targeted therapies for CLL treatment?
Reaping the Rewards of Innovative Care in CLL: From Targeted Strategies to Cellular Therapy
